CoChat

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study

Open access
Wolffenbuttel, Bruce H. R., Brugts, Michel P., Catarig, Andrei-Mircea, Clark, Alice, Kok, Maarten, Lieverse, Aloysius G., van Soest, Jaap · 2023 · Advances in Therapy

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

SURE Netherlands (NCT03929679) evaluated the use of once-weekly (OW) semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), in routine clinical care for individuals with type 2 diabetes (T2D). Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study. The primary endpoint was change from baseline to end of study (EOS; approx. 30 weeks) in glycated haemoglobin (HbA 1c ). Secondary endpoints were change from baseline to EOS in body weight (BW) and waist circumference (WC). Proportions of participants achieving predefined HbA 1c targets and weight-loss responses at EOS, safety, health-related quality of life (HRQoL) and treatment satisfaction were assessed. In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA. Mean baseline HbA 1c , BW and WC were 8.6%, 105.2 kg and 118.8 cm. In the 186 (88.2%) participants receiving semaglutide at EOS, mean reduction in HbA 1c with semaglutide was − 1.2%-points (95% [confidence interval] CI − 1.3; − 1.0; p < 0.0001), with 124 (70.5%), 95 (54.0%) and 65 (36.9%) participants achieving HbA 1c targets of < 8.0%, < 7.5% and < 7.0%, respectively. Mean reduction in BW was − 7.8 kg [95% CI − 8.7; − 6.8; p < 0.0001], corresponding to relative reduction of − 7.5% [95% CI − 8.4; − 6.6; p < 0.0001]. Improvements in WC (− 8.8 cm [95% CI − 10.4; − 7.2; p < 0.0001]), HRQoL and treatment satisfaction were observed, including across most Short-Form 36 Health Survey domains. One serious adverse drug reaction (cholecystitis) was reported. Eight participants (all receiving concomitant insulin) experienced severe or documented hypoglycaemia. Individuals with T2D treated with OW semaglutide experienced significant and clinically relevant improvements in glycaemic control and BW from baseline. These results from a diverse real-world population in the Netherlands support the use of OW semaglutide in treating adults with T2D in routine clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-022-02385-x

Cites

Statistics

Figures

Fig. 1 Proportions of participants at EOS achieving a HbA1c targets of < 8.0%, < 7.5%, < 7.0% and ≥ 1.0%-point reduction; b weight-loss responses of ≥ 3 and ≥ 5%. Data are from the EAS. BW, body weight; EAS, effectiveness analysis set; EOS, end of study; n, number of participants
Fig. 1 Proportions of participants at EOS achieving a HbA1c targets of < 8.0%, < 7.5%, < 7.0% and ≥ 1.0%-point reduction; b weight-loss responses of ≥ 3 and ≥ 5%. Data are from the EAS. BW, body weight; EAS, effectiveness analysis set; EOS, end of study; n, number of participantsCC BY-NC · PubMed Central
Fig. 2 Absolute changes in SF–36®v2 subdomain scores from baseline to EOS. *p < 0.0001; †p < 0.005. A higher SF-36®v2 score indicates greater functionality. Data are from the EAS. EOS, end of study; ns, not significant; SF-36®v2, 36-Item Short-Form Health Survey version 2
Fig. 2 Absolute changes in SF–36®v2 subdomain scores from baseline to EOS. *p < 0.0001; †p < 0.005. A higher SF-36®v2 score indicates greater functionality. Data are from the EAS. EOS, end of study; ns, not significant; SF-36®v2, 36-Item Short-Form Health Survey version 2CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 31 · Cited by 26

Metadata

Authors
Wolffenbuttel, B. H. R., Brugts, M. P., Catarig, A.-M., Clark, A., Kok, M., Lieverse, A. G., & van Soest, J.
Affiliations
  • University Medical Center Groningen (NL)
  • Ikazia Ziekenhuis (NL)
  • Novo Nordisk (Denmark) (DK)
  • Máxima Medisch Centrum (NL)
Corresponding author
Wolffenbuttel, Bruce H. R.
Venue
Advances in Therapy
Published
2022-12-21
Volume
40
Issue
3
Pages
920-933
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W4312106533
Cited by
26
References
31
Citations by year
2026: 3 · 2025: 5 · 2024: 11 · 2023: 7
FWCI
4.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by-nc)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
Novo Nordisk Pharma
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, type 2 diabetes, GLP-1 receptor agonists, HbA1c, HbA1c targets, weight loss, waist circumference, real-world effectiveness, health-related quality of life, treatment satisfaction, safety, metformin, basal insulin, routine clinical practice
MeSH terms
Semaglutide, Adolescent, Adult, Body Weight, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Insulin, Middle Aged, Netherlands, Quality of Life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study. https://app.cochat.ai/papers/10.1007/s12325-022-02385-x
The paper
Wolffenbuttel, B. H. R., Brugts, M. P., Catarig, A.-M., Clark, A., Kok, M., Lieverse, A. G., & van Soest, J. (2023). Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study. Advances in Therapy. https://doi.org/10.1007/s12325-022-02385-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.